Clearside Biomedical Inc’s filing revealed that its Director Thorp Clay acquired Company’s shares for reported $13800.0 on Feb 24 ’25. In the deal valued at $0.92 per share,15,000 shares were bought. As a result of this transaction, Thorp Clay now holds 176,141 shares worth roughly $88070.5.
Then, Chong Ngai Hang Victor bought 36,500 shares, generating $36,500 in total proceeds. Upon buying the shares at $1.00, the Chief Medical Officer now owns 100,000 shares.
Stifel downgraded its Clearside Biomedical Inc [CLSD] rating to a Hold from a a Buy in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who decreased its forecast for the stock in mid July from “a Buy” to “a Neutral”. Chardan Capital Markets also remained covering CLSD and has decreased its forecast on July 18, 2025 with a “Neutral” recommendation from previously “Buy” rating. Chardan Capital Markets started covering the stock on August 21, 2024. It rated CLSD as “a Buy”.
Price Performance Review of CLSD
On Friday, Clearside Biomedical Inc [NASDAQ:CLSD] saw its stock fall -7.72% to $0.5. Over the last five days, the stock has gained 21.56%. Clearside Biomedical Inc shares have fallen nearly -56.77% since the year began. Nevertheless, the stocks have fallen -47.66% over the past one year. While a 52-week high of $1.65 was reached on 02/07/25, a 52-week low of $0.29 was recorded on 07/21/25.
Levels Of Support And Resistance For CLSD Stock
The 24-hour chart illustrates a support level at 0.4691, which if violated will result in even more drops to 0.4411. On the upside, there is a resistance level at 0.5361. A further resistance level may holdings at 0.5751.
How much short interest is there in Clearside Biomedical Inc?
A steep rise in short interest was recorded in Clearside Biomedical Inc stocks on 2025-07-15, dropping by -0.19 million shares to a total of 0.16 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 0.35 million shares. There was a decline of -114.66%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 25, 2024 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $5 price target.
